Lir Life Sciences Corp. (CVE:SKNY)

BRIEF

published on 01/30/2026 at 00:05, 1 day 14 hours ago

LIR Life Sciences Reports Promising Interim Preclinical Results

Transdermal Delivery Preclinical Results GLP/GIP Therapies CPP Technology Blood Glucose Control
PRESS RELEASE

published on 01/30/2026 at 00:00, 1 day 14 hours ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
LIR Life Sciences Corp. announces positive interim results from a mouse study on CPP-enabled, needle-free delivery of GLP/GIP therapies, demonstrating glucose control potential

Interim Results Lir Life Sciences Corp. GLP/GIP Therapies CPP-enabled Delivery Skin-applied Formulation
BRIEF

published on 01/23/2026 at 00:05, 8 days 14 hours ago

LIR Life Sciences Finalizes Study Design for Evaluating Transdermal Agents

Transdermal Delivery LIR Life Sciences Therapeutic Macromolecules Porcine Skin Model Needle-free Therapies
PRESS RELEASE

published on 01/23/2026 at 00:00, 8 days 14 hours ago

LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules
LIR Life Sciences Corp. announces study design for transdermal penetration of therapeutic macromolecules using ex vivo porcine skin. Focus on needle-free delivery strategies for larger therapeutics

Needle-free Delivery LIR Life Sciences Therapeutic Macromolecules Transdermal Penetration Ex Vivo Porcine Skin
BRIEF

published on 01/16/2026 at 00:05, 15 days 14 hours ago

LIR Life Sciences Initiates Animal Study on Transdermal Obesity Therapies

Transdermal Delivery Obesity Therapy Animal Study LIR Life Sciences GLP/GIP-based
PRESS RELEASE

published on 01/16/2026 at 00:00, 15 days 14 hours ago

LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies
LIR Life Sciences Corp. announces a controlled comparative animal study to evaluate needle-free transdermal delivery of GLP/GIP-based obesity therapies. Study aims to advance transdermal platform and simplify treatment for obesity

Lir Life Sciences Corp. Obesity Therapies GLP/GIP-based Controlled Study Needle-free Transdermal Delivery
BRIEF

published on 01/09/2026 at 00:05, 22 days 14 hours ago

LIR Life Sciences Collaborates with Neuland Labs on Peptide Development

R&D Collaboration LIR Life Sciences Neuland Laboratories Cell Penetrating Peptides Transdermal Platform
PRESS RELEASE

published on 01/09/2026 at 00:00, 22 days 14 hours ago

LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
LIR Life Sciences Corp. enters R&D Agreement with Neuland Labs for peptide formulations. Neuland Labs to provide services for preclinical evaluation and future collaboration

Lir Life Sciences Corp. Neuland Labs R&D Agreement Peptide Formulations Preclinical Evaluation
BRIEF

published on 12/19/2025 at 00:05, 1 month 12 days ago

LIR Life Sciences Appoints Dr. Peter Singer as Scientific Advisor

Obesity Treatment Health Innovation LIR Life Sciences Scientific Advisor Peter Singer
PRESS RELEASE

published on 12/19/2025 at 00:00, 1 month 12 days ago

LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
LIR Life Sciences Corp. announces Dr. Peter Singer, former WHO advisor, as Scientific Advisor. Focus on global obesity treatments & market making services

Market Making Services Lir Life Sciences Corp. Obesity Treatments Scientific Advisor Dr. Peter Singer

Published on 01/31/2026 at 03:15, 11 hours 17 minutes ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 12 hours 12 minutes ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 12 hours 52 minutes ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 14 hours 32 minutes ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 15 hours 32 minutes ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 12:25, 2 hours 7 minutes ago

JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 11 hours 47 minutes ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 16 hours 32 minutes ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 18 hours 22 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 18 hours 23 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches

View all EQS

Published on 01/30/2026 at 17:45, 20 hours 47 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 1 day 6 hours ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 20 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 20 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 20 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News